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ABSTRACT
Tuberculosis (TB)-associated uveitis is a common cause
of infectious uveitis in the developing world. Diagnosis
of TB uveitis remains a challenge. The role of interferon
gamma release assays (IGRAs) is uncertain. Herein we
summarise the available literature on the utility of IGRAs in
the diagnosis and management of TB uveitis. We searched
PubMed database from 1 August 2010 to 31 July 2020
using the following keywords alone and in combination:
‘interferon-gamma release assay’, ‘QuantiFERON’,
‘T-SPOT.TB’, ‘TB uveitis’, ‘serpiginous like choroiditis’,
‘tuberculoma’, ‘TB vasculitis’, ‘TB panuveitis’ and ‘ocular
tuberculosis’. Data from 58 relevant studies were collated.
The review is focused on currently marketed versions
of IGRA tests: QuantiFERON-TB Gold In-Tube assay,
QuantiFERON-TB Gold Plus assay (QFT-Plus) and T-SPOT.
TB. We found limited evidence regarding the diagnostic
utility of IGRA in patients with uveitis. No study was
identified evaluating the newer QFT test—the QFT-Plus—
in patients with uveitis. Similarly, there is lack of data
directly comparing QFT-Plus with T-SPOT.TB specifically
for the diagnosis of TB uveitis.

INTRODUCTION
Mycobacterium tuberculosis continues to be a
common pathogen infecting an estimated
10 million people in 2018 alone.1 Ocular
tuberculosis (OTB) is an extrapulmonary
form of tuberculosis (TB) with a multitude of
presentations. The reported incidence varies
considerably, but majority of patients present
with choroidal involvement.2 OTB rarely
occurs as a primary infection, mostly occurring secondary to haematogenous spread.3
Diagnosing OTB is a challenge because
a definitive diagnosis of OTB can only be
achieved by testing either tissue samples or
ocular fluids for M. tuberculosis. Obtaining
ocular samples is not without risks. Because
of the paucibacillary nature of the organism,
even the samples collected do not always
yield results, even with PCR testing.4 This
problem is compounded by the fact that OTB
can present with symptoms similar to other
ocular diseases. OTB may be categorised

into TB scleritis and TB uveitis (TBU). TBU
is further divided into tubercular anterior
uveitis, tubercular intermediate uveitis, tubercular posterior uveitis, tubercular panuveitis
and tubercular retinal vasculitis. Interestingly, OTB often does not present with other
systemic manifestations of TB.5
In the absence of a diagnostic gold standard
test, in 2015 Gupta et al6 proposed a classification for intraocular TB. It involves labelling
cases as confirmed, probable or possible TBU.
Microbiological verification from ocular
fluid/tissues is required to label a case as a
confirmed TBU. For a case to be marked as a
probable TBU, immunological evidence of TB
infection or documented exposure to TB is
required, along with at least one clinical sign
suggestive of OTB and microbiological, radiological or clinical evidence of extraocular TB
infection. A more lax criterion is acceptable
when diagnosing a patient as a possible TBU.
Interferon gamma release assay (IGRA) is
used in two out of three groups in the classification of TBU.
Historically tuberculin skin test (TST) has
been used to provide immunological evidence
of infection. However, it has low specificity
due to the false-
positive results in BCG-
vaccinated patients and in patients infected
with other non-
tuberculous mycobacteria.
This has led to its usefulness being called
into question.7 TST also has low sensitivity in
immunocompromised patients and is therefore not recommended in these groups based
on the current guidelines.8 IGRA was introduced in 2001. IGRA is an in vitro blood test
that measures the interferon gamma (IFN-γ)
released by T cells following stimulation by
antigens specific to M. tuberculosis. These antigens include early secreted antigenic target 6
(ESAT-6) and culture filtrate protein 10 (CFP10). These antigens are encoded by genes
in the region of difference 1 (RD1) locus
of the M. tuberculosis genome.9 Two types of
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commercial IGRA tests are currently available: QuantiFERON-TB assay (Cellestis/Qiagen, Carnegie, Australia)
and the T-SPOT.TB assay (Oxford Immunotec, Oxford,
UK). Both tests are approved by the US Food and Drug
Administration (FDA).
The aim of this review is to summarise the literature about the utility of IGRA test in the diagnosis and
management of TBU. Factors that may induce variability
in test results and make them less reproducible, such as
prevalence of disease, immune status and antituberculous treatment (ATT), and factors not directly related to
patients are briefly discussed as well.
Literature search
An electronic literature search was conducted from 1
August 2010 to 31 July 2020 of articles in the PubMed
database using the following keywords alone and in
combination: ‘interferon-gamma release assay’, ‘QuantiFERON’, ‘T-
SPOT.TB’, ‘TB uveitis’, ‘serpiginous like
choroiditis’, ‘tuberculoma’, ‘TB vasculitis’, ‘TB panuveitis’ and ‘ocular tuberculosis’. Manuscripts published in
the past 10 years in English were included. References of
included articles were also searched for relevant studies.

Figure 1

2

We included studies that met the following criteria:
investigated the use of currently marketed versions of
both tests (QuantiFERON-TB Gold In-Tube assay (QFT-
GIT), QuantiFERON-
TB Gold Plus assay (QFT-
Plus),
T-SPOT.TB or the premarket ELISpot version of T-SPOT.
TB). Studies were excluded if authors had failed to specify
which version of the QFT was being used and if the assays
were being used on a bodily fluid other than blood. For
data extraction, one reviewer abstracted relevant data
from the eligible studies, which was double-checked by a
second reviewer. Details have been provided in figure 1.
Types of tests
QuantiFERON-TB assay (QFT)
The first version of the QuantiFERON-TB test (QIFN)
was approved by the FDA as a diagnostic tool for latent
TB infection in 2001.10 It is an ELISA-based whole blood
test that uses peptides from the M. tuberculosis-specific
antigens. The result is reported as quantification of IFN-γ
in international units (IU) per millilitre. The patient is
considered positive for latent TB infection if the reported
value is above the cut-off specified by the manufacturer.
The QFT assay has four versions: QIFN, QFT-
Gold,

Flowchart of study selection process.
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Table 1 Mechanisms of actions of IGRAs
Test

Mechanism of action

QFT

 
QIFN

ELISA-based whole blood assay. Blood is collected in heparinised tubes containing antigens,
phytohaemagglutinin as a positive control and saline as a negative control. IFN-γ is quantified from supernatant
plasma using ELISA. The antigens used for each version are different (see below).
Antigens used: human, avian and bovine type PPDs.

 
QFT-G

Antigens used: ESAT-6 and CFP-10.

 
QFT-GIT

Antigens used: ESAT-6, CFP-10 and TB7.7.

 
QFT-Plus

Two antigen tubes used: TB1 and TB2. TB1 contains ESAT-6 and CFP-10. TB2 contains an additional set of
peptides targeted to induce response from CD8+ cells.
ELISPot assay in which peripheral blood mononuclear cells are processed. The cells are washed and counted,
and a standard number of cells are added into plates and stimulated with TB-specific antigens, ESAT-6 and
CFP-10. Cells responding to these antigens release IFN-γ, which is captured by IFN-γ antibodies.
A secondary enzyme-labelled antibody is added and binds to the captured IFN-γ. A detection reagent is added
which reacts with the enzyme-labelled antibody. This reaction produces spots, showing where the IFN-γ was
released. Spots are then counted.

T-SPOT.TB

CFP-10, culture filtrate protein 10; ESAT-6, early secreted antigenic target 6; IFN-γ, interferon gamma; IGRA, interferon gamma release assay;
PPDs, purified protein derivatives; QFT, QuantiFERON-TB assay; QFT-G, QuantiFERON-TB Gold; QFT-GIT, QuantiFERON-TB Gold In-Tube
assay; QFT-Plus, QuantiFERON-TB Gold Plus assay; QIFN, QuantiFERON-TB test; TB, tuberculosis.

QFT-GIT and QFT-Gold Plus. The mechanisms of action
of tests are summarised in table 1.
QuantiFERON-TB assay (QIFN)
This version used the whole purified protein derivative
(PPD) as the antigen: human, avian and bovine types.
Whole heparinised blood is incubated with these PPDs,
phytohaemagglutinin as a positive control and saline as
a negative control. The plasma is then collected, and the
IFN-γ is quantified using an ELISA kit.10 This product is
no longer marketed.
QuantiFERON-TB Gold assay
The second version received approval in 2005. Fresh heparinised whole blood is incubated with synthetic peptides
representing ESAT-6 and CFP-10, rather than with PPDs.
IFN-γ concentration is measured using ELISA.11 This
product is no longer marketed.
QuantiFERON-TB Gold In-Tube assay
The QFT-GIT assay was approved by the FDA in 2007.12
In QFT-GIT, whole blood is collected in three heparinised tubes, one containing stimulating antigens ESAT-6,
CFP-10 and TB7.7, a mitogen (positive control) tube, and
a nil (antigen-free) tube. After incubation, IFN-γ concentration is measured using an ELISA kit.13
Diagnostic accuracy
The sensitivity of QFT-
GIT reported in meta-
analyses
ranged between 69% and 89% and the specificity between
76% and 99% for active TB. Similarly, for latent TB infection, sensitivity was reported between 58% and 84% and
specificity between 71% and 89%.14–25 For TBU, sensitivity was 64% (95% CI 60% to 69%) and specificity was
99.5% (95% CI 98.8% to 99.9%) in a study conducted in
Singapore.17

QuantiFERON-TB Gold Plus assay
The fourth generation of QFT uses two antigen tubes:
TB1 and TB2. Both tubes contain the antigens ESAT-6
and CFP-10 (TB7.7 is not used in this assay). TB2
contains an additional set of peptides targeted to induce
a response from CD8+ cells.26 27 It was approved by the
FDA in June 2017.28
Diagnostic accuracy
The sensitivity of QFT-Plus reported in meta-analyses for
active TB was 94% and the specificity was 96%.20 21 For
latent TB infection, sensitivity was 91% and specificity was
95%.29 30 No study reported the diagnostic accuracy of
QFT-Plus among patients with TBU.
T-SPOT.TB assay
The T-SPOT.TB is an enzyme-linked immunosorbent spot
(ELISpot) assay in which peripheral blood mononuclear
cells are processed.31 It was licensed in the European
Union in July 2004 and received FDA premarket approval
in July 2008.32 These cells react with synthetic peptides
representing ESAT-6 and CFP-10, and IFN-γ antibodies
are used to bind to the IFN-γ as the cells release it. A
secondary antibody, which is enzyme-labelled, is added
which attaches to the bound IFN-γ. A detection reagent
is introduced which reacts with the enzyme-labelled antibody. This reaction produces IFN-γ producing spots,
which are then counted. The patient is considered to be
positive for TB infection if the number of spots in the TB
antigen well exceeds the provided threshold value.33
Diagnostic accuracy
The sensitivity of T-SPOT.TB reported in meta-analyses
ranged between 74% and 89% and the specificity between
59% and 96.8% for active TB. Similarly, for latent TB
infection, sensitivity ranged between 55% and 93% and
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specificity ranged between 76% and 93%.14 17 20 23 32 34–37
Three primary studies reported the diagnostic accuracy
of T-SPOT.TB assay for uveitis.17 34 36
Direct comparison of QFT-GIT and T-SPOT.TB for diagnosis of
TBU
In a 2-year prospective study conducted in Singapore,
QFT-
GIT and T-
SPOT.TB were performed in patients
with newly diagnosed uveitis.17 The authors stated that
GIT was a
regardless of the prevalence of TBU, QFT-
superior choice and should be used as a first-line test.
Regarding the usefulness of performing both tests in
combination, if both tests give a positive result, then the
likelihood of a tuberculous cause rises to 100%. However,
even if both tests are negative, the possibility of TB still
remains. For discordant results, QFT-GIT provided more
accurate readings than T-SPOT.TB and both were more
accurate than the TST. The authors concluded that QFT-
GIT was the optimal choice in tests to diagnose patients
with TBU. We were unable to find any study comparing
QFT-Plus and T-SPOT.TB tests. All reported diagnostic
accuracies of IGRAs in TBU are provided in table 2.
Sources of variability
Prevalence of disease (endemic versus non-endemic)
Spectrum bias or effect refers to the phenomenon in
which there is a variance in the performance of a test in
different clinical settings. This may arise due to a variation in prevalence of the disease in different studies.
Because of this effect, tests may not be as accurate in
populations different from the ones they were developed
in.38 Leeflang et al39 analysed data from 23 meta-analyses
and found there to be a statistically significant (p<0.05)
negative correlation between specificity and prevalence.
They theorised that this association was caused by clinical
variability (range in patient spectrum, different referral
pathways and reader expectations) and artefactual differences (distorted inclusion of patients, verification bias
and imperfect reference standard). WHO recommends
that IGRAs should not replace microbiological methods
of diagnosis of pulmonary and extrapulmonary TB in
low-
income and middle-
income countries (which may
have a higher incidence than high-income countries).40
Babu et al41 stated that in countries where TB is endemic
immune-based tests might not be very useful as they do
not directly detect the organism but show that an immune
response has taken place. In a study of 687 contacts of
patients with culture-confirmed systemic TB in France,
QFT-GIT’s positive predictive value for progression to TB
was 1.96%, while the negative predictive value was 99.8%.
This study supports the utility of QFT-GIT in a low prevalence setting.42 Kang et al43 conducted a multicentre study
to investigate the clinical usefulness of the T-SPOT.TB in
diagnosing active TB in China, a high burden country.
They found that there was a high number of false positives when using this test (43.6%, 95% CI 40.9% to 46.3%)
and did not recommend its use in a high burden country.
4

Immune suppression
Immune suppression secondary to corticosteroids reduces
the release of IFN-γ and therefore leads to the test being
less accurate in patients under treatment. Edwards et al44
demonstrated this in an ex vivo model study. They also
stated that in these patients, inducible protein 10 (IP-10)
might serve as a more reliable biomarker. Glucocorticoids are noted to have a significant influence on IGRAs
in children if treated for more than a week.45 Bao et al
found glucocorticoids to affect the mitogen-stimulated
response and therefore negatively affect the IGRA results
in both adults and children.46 47 QFT-Plus sensitivity was
noted to be lower among people with HIV/AIDS with
severe immunosuppression.48
An older study evaluating the clinical usefulness of
T-SPOT.TB in immunocompromised patients (53 with
malignancy, 29 patients with diabetes mellitus, 23 taking
immunosuppressive drugs and 14 with end-stage renal
disease) found T-SPOT.TB cannot be used alone to rule
in TB due to its poor specificity in these groups. They
found the usefulness to be particularly less in the group
taking immunosuppressive drugs.49 T-SPOT.TB test was
found not to be affected by CD4+ T lymphocyte count
(p=0.289), and it was stated that in HIV-infected patients
with low CD4+ T lymphocyte counts, T-SPOT.TB test may
be considered for latent TB infection diagnosis.50
Antituberculous treatment
In a study by Bao et al,46 44.4% of patients with active
(pulmonary or extrapulmonary) TB converted to a negative reading with the QFT-GIT after less than 3 months
of ATT. This is thought to be due to the bactericidal
effect of ATT on M. Tuberculosis, which reduces antigen
production and hence reduces antigen-stimulated IFN-γ
production.
However, another study reported that the effects of
therapeutic concentrations of ATT (isoniazid, rifampicin and ciprofloxacin) on IFN-γ and other cytokines
were comparatively small, but found that dexamethasone
caused a marked change in IFN-γ concentrations. The
authors hypothesised that large changes in IFN-γ were
due to effects of the treatment, rather than the immunomodulatory effects of these drugs.51
Factors unrelated to patients
Sources of variability unrelated to patients (eg, due
to manufacturing or analytical sources) can also
reduce the reliability of IGRA tests. The presence of
variability means that the changes in the results may
not have an immunological basis. A dichotomous
cut-off value leads to greater ambiguity in the interpretation of results. Pai et al9 categorised the known
sources of variability into manufacturing sources,
preanalytical sources, analytical sources (random
errors causing fluctuations in measurements) and
immunological sources (boosting by PPD and modulation by Pathogen Associated Molecular patterns
(PAMP)). Preanalytical sources represent the main
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138

191

120

40

2012

2013
Interferon γ release assay
for the diagnosis of uveitis
associated with tuberculosis:
a Bayesian evaluation in the
absence of a gold standard67
2014

Interferon-gamma release
assay as a diagnostic test
for tuberculosis-associated
uveitis34

Prospective head-to-
head study comparing
2 commercial interferon
gamma release assays for
the diagnosis of tuberculous
uveitis17

Evaluation of the accuracy of 2017
T-SPOT.TB for the diagnosis
of ocular tuberculosis in
a BCG-vaccinated, non-
endemic population36

 

 

 

Chile
(low TB
incidence)

Singapore
(mid TB
incidence)

Singapore
(mid TB
incidence)

Singapore
(mid TB
incidence)

Singapore
(mid TB
incidence)

Country
incidence

Patients with
uveitis

Patients with
uveitis

Patients with
uveitis

Patients with
uveitis

Patients with
uveitis

Population

TB uveitis

TB uveitis

TB uveitis

TB uveitis

TB uveitis

Target
condition

0.67 (0.60 to 0.74)

0.50 (0.33 to 0.67)

0.36

0.64 (0.60 to 0.69)

Sensitivity (95% CI)

Tertiary referral 0.80 (0.53 to 0.94)
centre

Eye hospital

Eye hospital

Eye hospital

Eye hospital

Setting

0.85 (0.62 to 0.96)

0.91 (0.88 to 0.93)

0.91 (0.88 to 0.93)

0.75

0.995 (0.988 to 0.999)

Specificity (95% CI)

ATT, antituberculous treatment; IGRAs, interferon gamma release assays; QFT-GIT, QuantiFERON-TB Gold In-Tube assay; TB, tuberculosis; TST, tuberculin skin test.

120

T-SPOT.TB

2014

Prospective head-to-
head study comparing
2 commercial interferon
gamma release assays for
the diagnosis of tuberculous
uveitis17

N

QFT-GIT

Year

Study (reference)

Diagnostic accuracies of IGRAs for uveitis

Assay

Table 2

Positive TST
with intraocular
inflammation
and positive
response to ATT.

Not specified.

None, a
Bayesian latent
class model used
instead.

Not specified.

Not specified.

Gold standard
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component of causes of variability and are the ones
most extensively researched. Gaur et al52 found that
blood volume variability affected the results, and standardising the blood volume to 0.8 mL may increase
assay sensitivity. They also found that shaking the nil
and TB antigen tubes separately at different strengths
contributed to variability in results. Multiple authors
have reported that removing the dichotomous cut-off
value and instead introducing a range would increase
the reliability and validity of the QFT-GIT.53 54 Jonsson
et al53 found that retesting of results that fell in either
the borderline negative or positive ranges resulted in
reversions or conversions that would otherwise have
been classified as false positives or negatives, leading
to possible undertreatment or overtreatment. The
T-
SPOT.TB uses a borderline category to indicate
that results in that range should be retested. Rego
and colleagues55 found that this range, rather than a
cut-off value, resulted in less false positives, as most
of those in the borderline range that were retested
turned out to be negative.
Utility of IGRA
Utility of IGRA in the diagnosis of TBU
Diagnostic test results should be interpreted carefully
based on the patient’s ocular signs and symptoms, age,
and comorbidities. Gupta et al56 defined this as the
pretest likelihood of a patient having OTB. If the pretest
likelihood is determined to be low, a positive test may
not determine that the patient has TB. Ang et al57 evaluated the usefulness of IGRA in the diagnosis of TBU.
They reported low sensitivity to exclude OTB. A Bayesian
latent class study by Agrawal et al58 also concluded that
QFT-GIT alone could not separate TBU from non-TBU.
Gineys et al59 state that the cut-off value for QFT, that is,
0.35 IU/mL, is too low for the diagnosis for uveitis, and
that raising this value might prevent unnecessary anti-TB
treatment. In another study testing 50 patients suspected
with TBU with QFT-Gold in India, Sudharshan et al60
found that the percentage of positive results was higher
in patients with conditions affecting the posterior uveitis,
especially serpiginous-
like choroiditis. Testing in 181
patients in a hospital in Korea led to similar results, with
posterior uveitis being a finding in 44.6% of patients with
a positive IGRA result.61 In a retrospective cohort study
conducted in Singapore, a mid-
level burden country,
including cases from August 2006 to February 2007, Ang
and colleagues62 found that QFT-GIT was not superior
to TST in sensitivity and was only slightly more specific.
They suggested that since QFT-GIT was only slightly superior to TST in the diagnosis of TBU, a combination of
both tests should be used.
Utility of IGRA in screening for latent TB before TNF treatment
Antitumour necrosis factor (TNF) agents are used
to treat immune-
mediated inflammatory disorders,
including uveitis. The use of these therapies leads to
immune suppression and may precipitate infections. One
6

concern is the conversion of a latent TB infection to an
active one. This concern has led many countries to make
latent TB screening mandatory before the commencement of anti-
TNF treatment. In contrast to what has
been reported about the effects of corticosteroid use on
QFT-Gold, Sargın et al63 found QFT-Gold and T-SPOT.
TB to be good alternatives to TST in rhuematoid arthritis
(RA) patients for latent TB detection as they were not
significantly affected by prior vaccinations or by corticosteroid use. Other studies have also found QFT-GIT to
be appropriate for screening latent TB.64 65 Due to poor
agreement between TST and QFT, researchers in Spain
recommended using both tests.66
CONCLUSION
This review highlights the lack of high-quality diagnostic accuracy studies evaluating IGRA tests for the
diagnosis of TBU. As the newer versions of QFT tests
are introduced, further studies are needed to determine their usefulness in clinical settings. No study
was identified evaluating the latest QFT assay—QFT-
Plus—for the diagnosis of TBU. Similarly, there is lack
of data directly comparing QFT-Plus with T-SPOT.TB
specifically for the diagnosis of TBU.
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